AstraZeneca PLC Earnings - Q4 2025 Analysis & Highlights
AstraZeneca PLC's Q4 2025 earnings call highlighted strong financial performance with significant revenue and EPS growth, driven by global demand for innovative medicines and a robust pipeline. The company discussed its strategic investments in R&D, manufacturing expansion, and key growth opportunities in Oncology, BioPharmaceuticals, and Rare Disease segments, while also addressing competitive landscapes and providing optimistic financial guidance for 2026.
Key Financial Results
Total revenue increased by 8% in 2025.
Product revenue increased by 10%, driven by continued global demand for innovative medicines.
Core EPS grew by 11%.
The company had 16 blockbuster medicines in 2025, with 17 medicines growing at double digits.
Core gross margin landed at 82% in 2025.
Core R&D expenses increased by 12%, reflecting growing investment opportunities in the pipeline.
SG&A expenses increased by only 3% in 2025.
SG&A expenses as a proportion of total revenue decreased from 28% in 2024 to 26% in 2025.
Operating profit increased by 9%.
Cash flow from operating activities increased by 23% to $14.6 billion in 2025.
CapEx increased by $1.1 billion to $3.3 billion.
Total deal payments in 2025 amounted to $4.2 billion.
Business Segment Results
Oncology delivered total revenues of $25.6 billion, an increase of 14% on the prior year or 17% excluding the 2024 Lynparza sales milestone.
Tagrisso achieved over $7 billion in full year revenues.
Imfinzi achieved over $6 billion in full year revenues.
Calquence achieved over $3.5 billion in full year revenues.
Enhertu achieved over $2.5 billion in AZ revenues.
BioPharmaceuticals medicines delivered total revenue up 5% to $23 billion.
R&I revenues were up by 10% in the fourth quarter, with revenue from growth medicines having increased by 27%.
CVRM revenues were 6% down on the prior year due to generic competition.
Rare Disease delivered total revenue of $9.1 billion in 2025, up 4% over the last year.
Ultomiris grew 15% in the quarter.
Strensiq grew 15%.
Capital Allocation
CapEx increased by $1.1 billion to $3.3 billion in 2025.
CapEx investment is anticipated to increase by approximately one-third versus 2025 for 2026.
Total deal payments in 2025 amounted to $4.2 billion.
Success-based milestones and sales payments relating to past deals are anticipated to total around $2.5 billion in 2026.
Interest-bearing debt is close to $30 billion.
Net debt to EBITDA ratio currently sits at 1.2 times.
A second interim dividend of $2.17 per share was confirmed, resulting in a full year 2025 declared dividend of $3.20 per share.
The annual declared dividend is intended to increase to $3.30 per share in 2026.
Industry Trends and Dynamics
The company noted that the weight management sector is in its initial steps, with the future involving better convenience, longer duration of action for injectables, and new mechanisms.
Biologic medicines continue to gain share among severe asthma patients.
ATTR cardiomyopathy is often underdiagnosed, leading to delayed diagnosis, poor prognosis, and high morbidity, highlighting the need for better diagnostics and innovative new treatment options.
The obesity market is considered quite immature, with significant room for improvement in combination therapies and quality of weight loss.
Cardiometabolism is identified as the biggest issue mankind is facing, with GLP-1 and SGLT2 treatments being foundational.
Competitive Landscape
Calquence maintains its class leadership position across major markets in front-line CLL.
In the United States, Calquence has seen its market share leadership grow.
Breztri is the fastest-growing medicine within the expanding fixed-dose triple class treating COPD.
Fasenra's positive momentum is expected to continue in 2026, with growth in emerging markets accelerating after inclusion in the National Reimbursement Drug List in China.
Saphnelo's IV formulation has gained market leadership in several major markets.
Lokelma's strong growth is anticipated to continue into 2026, driven by market leadership within the growing potassium binder class.
The company aims to be the first to introduce a BCL2 and BTKi combination finite CLL approach in the US.
Growth Opportunities and Strategies
The company aims to reach 25 blockbusters by 2030.
16 positive Phase III trial readouts in 2025 have a combined peak year sales potential of $10 billion.
43 approvals for medicines across major regions were secured in the last 12 months, sustaining growth into 2026.
The company is strengthening its manufacturing and R&D footprints in both the US and China.
Over 100 Phase III trials are ongoing, with 20 Phase III readouts expected in 2026, potentially driving another $10 billion of peak revenue.
Investments are focused on five technologies: weight management, ADC and radioconjugates, next-generation IO bispecifics, cell therapy, and gene therapy programs.
Oral GLP-1 (elecoglipron) is progressing into Phase III development in 2026 for obesity or type 2 diabetes.
Wainua is expected to have CARDIO-TTRansform readout in ATTR cardiomyopathy in the second half of 2026.
Tozorakimab (IL-33 biologic) Phase III program in COPD is anticipated to read out in the first half of 2026.
Efzimfotase alfa is expected to have readouts in the first half of 2026, with the potential to be several times the value of Strensiq.
Anselamimab demonstrated significant improvement in all-cause mortality and cardiovascular hospitalization in kappa light chain amyloidosis.
NI009 (fibril-depleting antibody for lambda light chain amyloidosis) development has been accelerated.
Cliramitug is in Phase III for ATTR cardiomyopathy, with enrollment completed ahead of schedule.
A Phase IIb of Wainua with cliramitug is planned to initiate.
Financial Guidance and Outlook
Total revenue is anticipated to grow by a mid- to high-single-digit percentage in 2026.
Core gross margin is anticipated to be broadly flat to slightly higher in 2026.
Core tax rate is expected to be between 18% and 22% in 2026.
Core EPS growth is projected to be a low-double-digit percentage at constant exchange rates.
A low-single-digit positive FX impact on total revenue and a neutral impact on core EPS are anticipated based on January average exchange rates.
R&D expenses are anticipated to be at the upper end of the low-20s percentage range of total revenue in 2026.
The company targets a mid-30s operating margin in 2026.
A step-up in core net finance expense is anticipated for 2026, driven by higher lease expenses and lower interest income.
CapEx investment is expected to increase by approximately one-third versus 2025 in 2026.
Success-based milestones and sales payments relating to past deals are anticipated to total around $2.5 billion in 2026.
The annual declared dividend is intended to increase to $3.30 per share in 2026.
